is a dipeptidyl peptidase IV (DPP4) inhibitor. Saxagliptin is marketed under the trade name ONGLYZA® by Bristol-Myers Squibb for the treatment of type 2 diabetes.
two amino acid derivatives (A) and (B), described in further detail hereinbelow, coupled in the presence of a coupling reagent. The amide coupling of (S)-a[[(l,l-dimethyleethoxy)carbonyl]amino]-3- hydroxytricyclo [188.8.131.52]decane-l-acetic acid (A) and (lS,3S,5S)-2-azabicyclo[3.1.0]hexane-3- carboxamide (B), subsequent dehydration of the primary amide and deprotection of the amine affords saxagliptin (C).
synthetic route is disclosed as follows:
Savage, Scott A., et al., "Preparation of Saxagliptin, a Novel DPP-IV Inhibitor", Organic Process Research & Development, 2009, vol. 13, pp. 1169-1176.
|US6395767||16 Feb 2001||28 May 2002||Bristol-Myers Squibb Company||Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method|
|US6995183||27 Jul 2004||7 Feb 2006||Bristol Myers Squibb Company||Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods|
|US7186846||28 Mar 2005||6 Mar 2007||Bristol-Myers Squibb Company||Process for preparing a dipeptidyl peptidase IV inhibitor and intermediates employed therein|
|US7214702||23 May 2005||8 May 2007||Bristol-Myers Squibb Company||Reacting the amide compound with phosphorus oxychloride in an organic solvent; treating the reaction mixture with water to form (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxytricyclo[184.108.40.206,7]dec-1-yl)-1-oxoethyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile-hydrochloride|
|US7223573||2 May 2005||29 May 2007||Bristol-Myers Squibb Company||Enzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors|
|US7420079||18 Nov 2003||2 Sep 2008||Bristol-Myers Squibb Company||Intermediates for making 1(alpha-amino-1-(cyclopropyl-fused pyrrolidinylcarbonyl)methyl)-3-hydroxyadamantanes, e.g., methyl 3-hydroxy-<a-oxotricyclo[220.127.116.11,7]decane-1-acetate|
|US7470810||11 Jan 2005||30 Dec 2008||Bristol-Myers Squibb Company||Such as 1-dodecane-thiotrifluoroacetate; alkyl/arylthiol is treated with trifluoroacetic anhydride in presence of pyridine, solvent (dichloromethane), and dimethylaminopyridine (DMAP) as catalyst; for protection of amino acids|
|US7741082||12 Apr 2005||22 Jun 2010||Bristol-Myers Squibb Company||Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor|
|US7943656||18 Apr 2008||17 May 2011||Bristol-Myers Squibb Company||Crystal forms of saxagliptin and processes for preparing same|
|US20060035954||8 Aug 2005||16 Feb 2006||Sharma Padam N||Ammonolysis process for the preparation of intermediates for DPP IV inhibitors|
|WO2001068603A2||5 Mar 2001||20 Sep 2001||Bristol Myers Squibb Co||Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use|
|WO2008131149A2||18 Apr 2008||30 Oct 2008||Squibb Bristol Myers Co||Crystal forms of saxagliptin and processes for preparing same|
|WO2010115974A1||9 Apr 2010||14 Oct 2010||Sandoz Ag||Crystal forms of saxagliptin|
|WO2011140328A1||5 May 2011||10 Nov 2011||Teva Pharmaceutical Industries Ltd.||Saxagliptin intermediates, saxagliptin polymorphs, and processes for preparation thereof|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US8748631 *||24 May 2012||10 Jun 2014||Apicore, Llc||Process for preparing saxagliptin and its novel intermediates useful in the synthesis thereof|
|US20130023671 *||24 May 2012||24 Jan 2013||Apicore, Llc||Process for preparing saxagliptin and its novel intermediates useful in the synthesis thereof|